Document is current
Any future updates will be listed below
-
Authors
Garberis, I. https://orcid.org/0000-0002-0501-8520
Gaury, V. https://orcid.org/0000-0003-3605-3027
Saillard, C. https://orcid.org/0000-0003-3061-839X
Drubay, D. https://orcid.org/0000-0002-9997-9727
Elgui, K.
Schmauch, B. https://orcid.org/0000-0002-9478-6395
Jaeger, A. https://orcid.org/0000-0003-2759-3494
Herpin, L. https://orcid.org/0000-0002-5535-0601
Linhart, J. https://orcid.org/0000-0002-8420-8495
Sapateiro, M.
Bernigole, F.
Kamoun, A. https://orcid.org/0000-0001-8403-1944
Filiot, A.
Tchita, O. https://orcid.org/0009-0008-0583-1723
Dubois, R.
Auffret, M.
Guillou, L. https://orcid.org/0009-0007-6266-432X
Bousaid, I.
Azoulay, M.
Lemonnier, J. https://orcid.org/0000-0002-8821-2168
Sefta, M.
Everhard, S.
Sarrazin, A.
Reboud, J-F
Brulport, F.
Dachary, J.
Pistilli, B. https://orcid.org/0000-0002-9184-7199
Delaloge, S. https://orcid.org/0000-0003-2106-9165
Courtiol, P.
André, F. https://orcid.org/0000-0001-5795-8357
Aubert, V.
Lacroix-Triki, M. https://orcid.org/0000-0002-6641-8536
- License Information
-
More Information
Article History
Received: 10 October 2024
Accepted: 4 June 2025
First Online: 1 July 2025
Change Date: 11 August 2025
Change Type: Update
Change Details: In the version of the article initially published, in the Data availability section, data access was available through email request and has now been updated to
Change Details: https://redcap.link/DataRequestClinicalTrialsGustaveRoussy
Change Details: in the HTML and PDF versions of the article.
Competing interests
: V.G., C.S., K.E., B.S., A.J., L.H., R.D., M.A., L.G., M.S., A.S., J.R., F.B., J.D., and V.A. are employees of Owkin Inc. S.D. reports grants and non-financial support from Pfizer, grants from Novartis, grants and non-financial support from AstraZeneca, grants from Roche Genentech, grants from Lilly, grants from Orion, grants from Amgen, grants from Sanofi, grants from Exact Sciences, grants from Servier, grants from MSD, grants from BMS, grants from Pierre Fabre, grants from Exact Sciences, grants from Besins, grants from European Commission grants, grants from French government grants, grants from Fondation ARC grants, grants from Taiho, grants from Elsan, outside the submitted work. F.A. declares institutional financial interests, research grants with Novartis, Pfizer, AstraZeneca, Eli Lilly, Daiichi, Roche, and Sanofi. B.P. reports Consulting fees from Astra Zeneca (institutional), Seagen (institutional), Gilead (institutional), Novartis (institutional), Lilly (institutional), MSD (institutional), Pierre Fabre (personal), Daiichi-Sankyo (institutional/personal); research funding (institutional) from Astra Zeneca, Daiichi-Sankyo, Gilead, Seagen, MSD, and Fondation ARC. Travel support: Astra Zeneca; Pierre Fabre; MSD; Daiichi-Sankyo. M.L.-T. reports consulting fees from Astra Zeneca (institutional/personal), Seagen (personal), Lilly (personal), MSD (institutional/personal), Pierre Fabre (personal), Daiichi-Sankyo (institutional/personal), Myriad Genetics (personal), Exact Sciences (personal), Roche Diagnostics ((institutional/personal); research funding (institutional) from Roche Diagnostics, Daiichi-Sankyo, and Pierre Fabre. Travel support: AstraZeneca, Seagen, and Daiichi-Sankyo. The remaining authors declare no competing interests.
